PSI is a global contract research organization (CRO) specializing in the on-time delivery of pivotal Phase 2 and 3 clinical trials.
Last updated September 26, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
PSI (also known as PSI CRO) is a privately held, global contract research organization (CRO) headquartered in Zug, Switzerland. The company positions itself as "The Global CRO You Can Trust," with a core value proposition built around delivering pivotal Phase 2 and Phase 3 clinical trials on time and on budget. PSI's services span the full clinical trial lifecycle, from feasibility and site identification through startup, enrollment, and study completion, supported by an extensive and diverse team of experts operating across 58 countries. PSI's therapeutic expertise covers a broad range of indications, including oncology (breast, lung, prostate, colorectal, ovarian cancers), gastroenterology (inflammatory bowel diseases, Crohn's disease, ulcerative colitis), hematology (multiple myeloma, lymphomas, leukemias, hemophilia), cell and gene therapy (CAR-T, gene editing, stem cell therapy, immunotherapy), neurology (multiple sclerosis, Alzheimer's, Parkinson's, stroke), infectious diseases (UTI, CAP/VAP/HAP, sepsis, hepatitis), radiopharmaceuticals, respiratory diseases (COPD, IPF, asthma), and other areas such as allergy, immunology, rheumatology, and cardiology. The company has built its reputation on a contrarian approach to industry norms. While acknowledging that delays and budget overruns have become commonplace in clinical research, PSI claims an on-time enrollment rate of over 90% for pivotal Phase 2 and 3 trials and a 90% repeat and referral rate among its biopharma clients. PSI describes itself as often coming to the rescue when trials fall behind, and its internal rallying cry, "We Can Do Hard Things," reflects this positioning. PSI has also invested in technology platforms to support its service delivery. These include a feasibility platform designed to protect trials from delays and budget overruns, and an agentic AI platform built to accelerate study milestones. In 2025, the company launched SYNETIC™, a platform aimed at speeding up site identification, startup, and enrollment in pivotal studies. PSI maintains a thought leadership presence through initiatives such as "PSI on Point" and congress highlights focused on topics like AI in clinical trials. With approximately 30 years of operation, PSI has established itself as a trusted partner for biopharma sponsors seeking reliable, timeline-obsessed clinical trial execution. The company remains privately held and continues to expand its global footprint and technological capabilities.
History
PSI was founded approximately 30 years ago, establishing itself as a contract research organization (CRO) focused on the execution of pivotal Phase 2 and Phase 3 clinical trials. From its headquarters in Zug, Switzerland, the company grew into a global operation with experts deployed across 58 countries. A defining characteristic of PSI's history has been its contrarian stance against industry norms. While the clinical research industry has long accepted delays and budget overruns as inevitable, PSI built its brand around the promise of on-time delivery. The company claims that over 90% of pivotal Phase 2 and 3 trials it manages achieve on-time enrollment, and that 90% of its clients are repeat or referral customers. PSI has frequently positioned itself as a rescue partner for sponsors whose trials have fallen behind schedule. Over the decades, PSI expanded its therapeutic expertise to cover a wide range of areas, including oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory medicine. This breadth allowed the company to serve diverse biopharma sponsors across multiple indications. In recent years, PSI has invested in digital and AI-driven platforms to enhance its service delivery. The company developed a feasibility platform designed to protect trials from delays and budget overruns, and an agentic AI platform built to accelerate study milestones. In 2025, PSI launched SYNETIC™, a platform specifically aimed at speeding up site identification, startup, and enrollment in pivotal studies. The company also maintains a thought leadership presence through initiatives such as "PSI on Point" and congress highlights, with a focus on topics like AI in clinical trials. Throughout its history, PSI has remained privately held, allowing it to maintain its independent positioning and client-focused approach. The company continues to operate globally, emphasizing its rallying cry, "We Can Do Hard Things," as a reflection of its commitment to tackling complex clinical trial challenges.
- 2025
PSI launches SYNETIC™ to speed up site ID, startup, and enrollment in pivotal studies.
- 2025
PSI publishes its annual update, 'Built to deliver'.
- 1995
PSI founded as a contract research organization.
Products and positioning
The global CRO you can trust, delivering pivotal Phase 2 & 3 clinical trials on time and on budget.
Feasibility platform
A platform built to protect clinical trials from delays and budget overruns.
Agentic AI platform
A platform built to accelerate study milestones.
SYNETIC™
A platform to speed up site ID, startup, and enrollment in pivotal studies.
Recent events
Reported
PSI announces acquisition of Propel International[3]
PSI announced that it was acquiring Propel International, a talent assessment and development consultancy. PSI said Propel’s addition would expand its international presence and double its existing team in the Middle East.
Reported
PSI acquires OPRA Psychology Group[4]
PSI's talent management business unit acquired OPRA Psychology Group, a business psychology and HR specialist team based in Australia, New Zealand and Singapore.
Reported
PSI announces acquisitions of Human Scope and Ottmann Global Partners[5]
PSI announced that it would acquire Human Scope, serving Hong Kong and the Greater China region, and Germany-based Ottmann Global Partners.
Reported
PSI and NCARB announce exam administration partnership[6]
PSI announced a partnership with NCARB to provide exam delivery services for NCARB's Architect Registration Examination. PSI's exam administration services are scheduled to begin in 2021.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/psi · Editorial policy · How profiles are compiled